CRSP - CRISPR Therapeutics AG

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual

Income Statement

All numbers in thousands
Breakdown
ttm
12/30/2018
12/30/2017
12/30/2016
12/30/2015
Total Revenue
212,689
3,124
40,997
5,164
247
Cost of Revenue
-
-
-
-
-
Gross Profit
-
-
-
-
-
Operating Expenses
Research Development
159,402
113,773
69,800
42,238
12,573
Selling General and Administrative
62,758
48,294
35,845
31,056
13,403
Total Operating Expenses
222,160
162,067
105,645
73,294
25,976
Operating Income or Loss
-9,471
-158,943
-64,648
-68,130
-25,729
Interest Expense
-
0
0
8,050
108
Total Other Income/Expenses Net
-1,125
-5,485
-1,960
53,462
16
Income Before Tax
-10,596
-164,428
-66,608
-22,718
-25,821
Income Tax Expense
678
553
1,749
484
7
Income from Continuing Operations
-11,274
-164,981
-68,357
-23,202
-25,828
Net Income
-11,274
-164,981
-68,357
-23,202
-25,828
Net Income available to common shareholders
-11,274
-164,981
-68,357
-23,202
-25,828
Reported EPS
Basic
-
-3.44
-1.71
-1.89
-1.26
Diluted
-
-3.44
-1.71
-1.89
-1.26
Weighted average shares outstanding
Basic
-
47,964
40,057
12,257
20,241
Diluted
-
47,964
40,057
12,257
20,241
EBITDA
-
-158,943
-61,624
-13,743
-25,586